Top 10 at 10: High grade gold, iron ore, and an AI NVIDIA collab

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data.

It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.

The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has started trading.

 

WINNERS

Stocks highlighted in yellow have made market-moving announcements (click headings to sort).

WordPress Table

Arrow Minerals (ASX:AMD) has uncovered two high grade (+58% fe) iron ore targets from rock chip sampling at Kalako, part of the flagship Simandou North project in Guinea.

IT stock Cirrus (ASX:CNW) announced a collaboration with NASDAQ-listed NVIDIA “to leverage the power of accelerated computing and artificial intelligence (AI) to drive innovation, improve efficiency, and promote sustainability across the Australian resources sector”.

And Iceni Gold (ASX:ICL) has picked up more high grade rock chips up to 3880g/t gold at Everleigh Well, part of the 14 Mile Well project in WA.

Analysis of soil anomalies, rock chips and (+800) gold nuggets indicate the potential for a large buried intrusion, the company says.

 

LOSERS

Stocks highlighted in yellow have made market-moving announcements (click headings to sort).

WordPress Table

This week’s big winner Everest Metals (ASX:EMC) has given back of chunk of its gains after a small drilling program at the Mt Edon lithium-rubidium project returned sub-economic lithium results.

However, EMC COO Simon Phillips says the hunt for the source of this recently discovered LCT mineralisation continues “with the proposed stage 2 drilling campaign set to commence in early August 2023”.

And Atomo Diagnostics (ASX:AT1) will raise $1.25m at 3.6c per share – a 30.8% discount to the last closing price.

Funds raised will be used to expand and accelerate sales, marketing, business development and new product registration activities with a focus on the US market following the recent FDA 510(k) approval for Lumos Diagnostics’ FedbriDx test on the Atomo Pascal platform.